Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Moderate Buy” by Analysts

Core Insights - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has received a consensus rating of "Moderate Buy" from nine research firms, with one sell rating, seven buy ratings, and one strong buy rating [2] - The average one-year price target among brokerages covering the stock is $3.8571 [2] Analyst Ratings - D. Boral Capital has restated a "buy" rating with a price target of $2.00 [3] - HC Wainwright has also restated a "buy" rating with a price target of $4.00 [3] - Benchmark has lowered its price target from $14.00 to $7.00 while assigning a "speculative buy" rating [3] - Weiss Ratings has reiterated a "sell (e+)" rating [3] - Wall Street Zen upgraded the stock from a "sell" rating to a "hold" rating [3] Stock Performance - Reviva Pharmaceuticals' stock opened at $0.31, with a 10.4% increase [4] - The company's market capitalization is $35.31 million, with a P/E ratio of -0.67 and a beta of -0.02 [4] - The stock has a 12-month low of $0.25 and a high of $2.17 [4] Earnings Results - The company reported an EPS of ($0.06) for the last quarter, exceeding the consensus estimate of ($0.11) by $0.05 [5] - Analysts anticipate an EPS of -0.97 for the current year [5] Institutional Activity - Geode Capital Management increased its position by 6.9%, owning 448,202 shares valued at $171,000 [6] - NewEdge Advisors acquired a new stake worth about $58,000 [6] - XTX Topco Ltd and Lido Advisors also acquired new positions valued at approximately $31,000 and $37,000, respectively [6] - Millennium Management raised its stake by 15.0%, owning 1,711,221 shares valued at $631,000 [6] - Institutional investors and hedge funds own 63.18% of the stock [6] Company Overview - Reviva Pharmaceuticals is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of prescription drug products in the U.S. and select international markets [7] - The company targets under-promoted, off-patent pharmaceuticals to enhance patient compliance and therapeutic outcomes [7] - Core activities include identifying FDA-approved drug candidates and developing formulations for niche or underserved patient populations [8]